203 related articles for article (PubMed ID: 30654739)
21. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
Cento V; Perno CF
J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
[TBL] [Abstract][Full Text] [Related]
22. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500
[TBL] [Abstract][Full Text] [Related]
23. Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Colangeli V; Borderi M; Testi D; Granozzi B; Bon I; Re MC; Viale P
J Antimicrob Chemother; 2020 Nov; 75(11):3327-3333. PubMed ID: 32728708
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
Mondi A; Fabbiani M; Ciccarelli N; Colafigli M; D'Avino A; Borghetti A; Gagliardini R; Cauda R; De Luca A; Di Giambenedetto S
J Antimicrob Chemother; 2015; 70(6):1843-9. PubMed ID: 25885326
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years.
Calza L; Colangeli V; Legnani G; Cretella S; Bon I; Viale P
AIDS Res Hum Retroviruses; 2024 Feb; 40(2):73-79. PubMed ID: 37335031
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients.
Vizcarra P; Fontecha M; Monsalvo M; Vivancos MJ; Rojo A; Casado JL
Antivir Ther; 2019; 24(6):467-471. PubMed ID: 31172977
[TBL] [Abstract][Full Text] [Related]
27. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients.
Fabbiani M; Masini M; Rossetti B; Ciccullo A; Borghi V; Lagi F; Capetti A; Colafigli M; Panza F; Baldin G; Mussini C; Sterrantino G; Farinacci D; Montagnani F; Tumbarello M; Di Giambenedetto S
Viruses; 2023 May; 15(5):. PubMed ID: 37243208
[TBL] [Abstract][Full Text] [Related]
29. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding.
Ciccullo A; Borghi V; Giacomelli A; Cossu MV; Sterrantino G; Latini A; Giacometti A; De Vito A; Gennari W; Madeddu G; Capetti A; d'Ettorre G; Mussini C; Rusconi S; Di Giambenedetto S; Baldin G
J Acquir Immune Defic Syndr; 2021 Nov; 88(3):234-237. PubMed ID: 34446677
[TBL] [Abstract][Full Text] [Related]
30. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
[TBL] [Abstract][Full Text] [Related]
31. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
Capetti AF; Cossu MV; Orofino G; Sterrantino G; Cenderello G; De Socio GV; Cattelan AM; Soria A; Rusconi S; Riccardi N; Baldin GM; Niero FP; Barbarini G; Rizzardini G
BMC Infect Dis; 2017 Sep; 17(1):658. PubMed ID: 28964268
[TBL] [Abstract][Full Text] [Related]
32. Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.
Antoniou T; Szadkowski L; Walmsley S; Cooper C; Burchell AN; Bayoumi AM; Montaner JS; Loutfy M; Klein MB; Machouf N; Tsoukas C; Wong A; Hogg RS; Raboud J;
BMC Infect Dis; 2017 Apr; 17(1):266. PubMed ID: 28399819
[TBL] [Abstract][Full Text] [Related]
33. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
Hui X; Gan X; Li Q; Sun W
Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525
[TBL] [Abstract][Full Text] [Related]
34. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
[TBL] [Abstract][Full Text] [Related]
35. HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.
Auclair M; Guénantin AC; Fellahi S; Garcia M; Capeau J
PLoS One; 2020; 15(1):e0226924. PubMed ID: 31971958
[TBL] [Abstract][Full Text] [Related]
36. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
38. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Maggiolo F; Gulminetti R; Pagnucco L; Digaetano M; Benatti S; Valenti D; Callegaro A; Ripamonti D; Mussini C
BMC Infect Dis; 2017 Mar; 17(1):215. PubMed ID: 28302065
[TBL] [Abstract][Full Text] [Related]
39. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
De Miguel R; Rial-Crestelo D; Dominguez-Dominguez L; Montejano R; Esteban-Cantos A; Aranguren-Rivas P; Stella-Ascariz N; Bisbal O; Bermejo-Plaza L; Garcia-Alvarez M; Alejos B; Hernando A; Santacreu-Guerrero M; Cadiñanos J; Mayoral M; Castro JM; Moreno V; Martin-Carbonero L; Delgado R; Rubio R; Pulido F; Arribas JR;
EBioMedicine; 2020 May; 55():102779. PubMed ID: 32408111
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
